(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 32.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Arcturus Therapeutics Holdings's revenue in 2023 is $296,237,000.On average, 3 Wall Street analysts forecast ARCT's revenue for 2023 to be $5,347,338,733, with the lowest ARCT revenue forecast at $4,035,223,132, and the highest ARCT revenue forecast at $7,578,202,489. On average, 3 Wall Street analysts forecast ARCT's revenue for 2024 to be $7,654,363,985, with the lowest ARCT revenue forecast at $3,493,541,192, and the highest ARCT revenue forecast at $11,392,156,432.
In 2025, ARCT is forecast to generate $20,116,950,203 in revenue, with the lowest revenue forecast at $4,707,582,165 and the highest revenue forecast at $31,343,796,103.